Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis133
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome73
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis41
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI39
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)30
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study30
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment30
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients28
Cardio-rheumatology: integrated care and the opportunities for personalized medicine28
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data28
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis28
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients27
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry26
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review26
Calcineurin inhibitors in systemic sclerosis – a systematic literature review25
Health disparities in rheumatoid arthritis23
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study22
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors22
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials22
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids21
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs20
A glimpse into the future of systemic lupus erythematosus20
0.90412998199463